Nucleic Acid, Nucleoside, or Nucleotide
Novartis Expands Leqvio’s Potential After Successful Phase III Study Demonstrates Significant Cholesterol Reduction
Novartis, Leqvio, inclisiran, cholesterol reduction, Phase III study, ASCVD, LDL-C, cardiovascular disease
Bayer and NextRNA Therapeutics Collaborate on $547 Million Deal to Develop Innovative Cancer Therapies Targeting Long Non-Coding RNAs
Bayer, NextRNA Therapeutics, lncRNA, small molecules, cancer, oncology, partnership, drug development
Novartis and Versant Ventures Launch Borealis Biosciences to Develop RNA Medicines for Kidney Diseases
Borealis Biosciences, Novartis, Versant Ventures, RNA medicines, kidney diseases, xRNA technology, biotechnology, startup, kidney research, RNA therapeutics.
FDA Approves Updated COVID-19 Vaccines from Pfizer and Moderna for Enhanced Protection
COVID-19 vaccines, FDA approval, mRNA vaccines, Pfizer, Moderna, updated vaccines, KP.2 variant, JN.1 lineage, emergency use authorization, vaccination guidelines.
FTC Supports FDA’s Simplified Biosimilar Interchangeability Plan
biosimilars, interchangeable biosimilars, FDA, FTC, pharmaceutical competition, drug pricing
Syros Discontinues Mid-Stage Tamibarotene Program in Frontline Acute Myeloid Leukemia (AML)
Syros Pharmaceuticals, Tamibarotene, Acute Myeloid Leukemia (AML), Clinical Trial, SELECT-AML-1, Venetoclax, Azacitidine, RARα Agonist, Futility Analysis
Biotech Startup Airna Secures $60M to Advance RNA-Editing Therapy for Alpha-1 Antitrypsin Deficiency
Airna, RNA editing, alpha-1 antitrypsin deficiency, AATD, biotech startup, genetic medicine, ADAR, CRISPR, RNA therapy
BioNTech-Regeneron vs. Moderna-Merck.Cancer Vaccine and PD-1 Inhibitor Combinations.
, BioNTech, Regeneron, Moderna, Merck, Cancer Vaccine, PD-1 Inhibitor, mRNA Technology, Melanoma, Immunotherapy, Clinical Trials,
BioNTech and Regeneron Achieve Positive Phase II Results for mRNA Cancer Vaccine Combo in Melanoma
BioNTech, Regeneron, mRNA cancer vaccine, melanoma, Phase II trial, Libtayo, cemiplimab, BNT111, immunotherapy
BioNTech and Regeneron Achieve Significant Response Rate Success in Phase 2 Trial for mRNA Cancer Immunotherapy BNT111
BioNTech, Regeneron, mRNA immunotherapy, BNT111, Phase 2 trial, melanoma, cancer treatment, PD-1 checkpoint inhibitor, cemiplimab, FixVac platform, uridine mRNA-LPX technology